Middleton, Massachusetts, October 1, 2026
MavriX Bio, a clinical-stage biotechnology company developing genetic therapies for severe neurological disorders, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its investigational gene therapy MVX-220 for the treatment of Angelman syndrome (AS). The designation represents an important regulatory milestone for the company as it advances a potential genetic medicine for a rare and debilitating neurogenetic disorder associated with loss of function of the maternally inherited UBE3A gene. Angelman syndrome primarily affects neurological development and is associated with significant unmet medical needs, while there are currently no approved treatments addressing the underlying genetic cause of the disorder.
FDA Designation Highlights Unmet Need in Angelman Syndrome
The FDA grants Rare Pediatric Disease Designation to investigational therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age and impact fewer than 200,000 people in the United States. For MavriX Bio, the designation recognizes the potential importance of MVX-220 in addressing a serious rare disease for which new therapeutic approaches are urgently needed. The company said the FDA milestone reinforces its commitment to developing innovative genetic treatments for individuals and families affected by Angelman syndrome. If MVX-220 ultimately receives FDA approval and meets applicable statutory requirements, the program may also become eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Such a voucher can potentially be used by an eligible sponsor to obtain priority review of a subsequent marketing application or may be transferred or sold to another sponsor.
MVX-220 Targets the Genetic Cause of Angelman Syndrome
MVX-220 is an investigational AAV-based gene therapy designed to deliver a functional copy of the UBE3A gene to neurons. The approach is intended to restore functional UBE3A expression and address the underlying genetic mechanism responsible for Angelman syndrome. The program is currently being evaluated in the first-in-human ASCEND-AS Phase 1/2 clinical study, identified as NCT07181837. The study is assessing the safety and tolerability of MVX-220 in both adult and pediatric participants living with different genetic forms of Angelman syndrome, including deletion, uniparental disomy, and imprinting center defects. The development of MVX-220 has involved collaboration across biotechnology, academic research, and patient-focused organizations. The program was developed with funding from the Foundation for Angelman Syndrome Therapeutics (FAST) and advanced into clinical development by MavriX Bio following a research collaboration with GEMMABio. The therapy was developed from research conducted by Jim Wilson’s academic team, with FAST supporting development and nonclinical research activities before the program was licensed to MavriX Bio through FAST’s AS2Bio drug development accelerator.
Advertisement
Clinical Development Moves Forward
The FDA designation comes as MavriX Bio continues clinical development of MVX-220 as a potential one-time gene replacement therapy. By targeting neurons with a functional UBE3A gene, the investigational treatment is designed to address the biological root of Angelman syndrome rather than simply managing individual symptoms. The ongoing ASCEND-AS study is therefore an important step in determining the therapy’s safety and tolerability across affected patient populations. Future clinical development and regulatory milestones will be important in determining whether the approach can ultimately demonstrate sufficient evidence to support broader development and potential approval.
For the broader gene therapy and rare disease biotechnology sector, the FDA’s Rare Pediatric Disease Designation for MVX-220 highlights continued efforts to develop targeted genetic medicines for disorders with limited or no disease-modifying treatment options. MavriX Bio’s progress also demonstrates how AAV-based gene delivery, academic research, patient foundations, and biotechnology development can converge to advance potential treatments for rare neurological conditions.
Source: MavriX Bio press release
